Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry
Language English Country Great Britain, England Media print-electronic
Document type Journal Article
PubMed
38050405
DOI
10.1002/hon.3240
Knihovny.cz E-resources
- Keywords
- COVID-19, SARS-CoV-2, hematological malignancy, multiple myeloma,
- MeSH
- COVID-19 * MeSH
- Humans MeSH
- Multiple Myeloma * therapy MeSH
- Pandemics MeSH
- Registries MeSH
- SARS-CoV-2 MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109 /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.
Ankara University Ankara Turkey
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo Alessandria Italy
Azienda Ospedaliera San Gerardo Monza Monza Italy
Centro Hospitalar e Universitário São João Porto Portugal
CIBERINFEC Instituto de Salud Carlos 3 Madrid Spain
Clinica Malattie Infettive Ospedale Policlinico San Martino IRCCS Genoa Italy
Complejo Hospitalario de Navarra Iruña Pamplona Spain
Departament de Medicina Universitat Autònoma de Barcelona Bellaterra Spain
Department of Clinical and Biological Sciences University of Turin Turin Italy
Department of Health Sciences University of Genoa Genoa Italy
Department of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria
Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Hematology Research Unit Hospital Universitario de Burgos Burgos Spain
Department of Hematology University Hospital Dubrava Zagreb Croatia
Department of Infectious Diseases Karolinska University Hospital Stockholm Sweden
Department of Internal Medicine ADRZ Goes Netherlands
Department of Medicine Section of Hematology University of Verona Verona Italy
Department of Nephrology and Infectious diseases AZ Sint Jan Brugge Oostende AV Brugge Belgium
Division of Hematology Dokuz Eylul University Izmir Turkey
Ematologia con Trapianto Ospedale Dimiccoli Barletta Barletta Italy
Federal University of Rio de Janeiro Rio de Janeiro Brazil
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
Fundacion Jimenez Diaz University Hospital Health Research Institute IIS FJD Madrid Spain
German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany
Hematology and Stem Cell transplan Unit Vito Fazzi Italy
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
Hematology and Stem Cell Transplantation Unit AOUC Policlinico Bari Italy
Hematology Department Hospital Universitario de Salamanca Salamanca Spain
Hematology Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
Hematology Unit ASST Spedali Civili Brescia Italy
Hematology Unit Center for Translational Medicine Azienda USL Toscana NordOvest Livorno Italy
Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Hospital Clinic Barcelona Spain
Hospital Escuela de Agudos Dr Ramón Madariaga Posadas Argentina
Hospital Nuestra Señora de Sonsoles Ávila Spain
Hospital Universitario Puerta de Hierro Majadahonda Spain
Hospital University of Parma Hematology and Bone Marrow Unit Parma Italy
IBSAL Centro de Investigación del Cáncer IBMCC Salamanca Spain
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS Ospedale San Raffaele Milan Italy
Istituto Oncologico della Svizzera Italiana Bellinzona Switzerland
King's College Hospital London UK
King's College London London UK
La Paz University Hospital Madrid Spain
NIHR Oxford Biomedical Research Centre Churchill Hospital Oxford UK
Oncology Center Mansoura University Mansoura Egypt
Portuguese Institute of Oncology Lisbon Portugal
San Luigi Gonzaga Hospital Orbassano Orbassano Italy
School of Medicine University of Zagreb Zagreb Croatia
Università Milano Bicocca Milan Italy
University Clinical Center Serbia Medical Faculty University Belgrade Belgrade Serbia
University Hospital Centre Rijeka Rijeka Croatia
University Hospital Centre Zagreb Zagreb Croatia
University Hospital Hradec Králové Hradec Králové Czech Republic
University Hospital Olomouc Olomouc Czech Republic
See more in PubMed
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892. https://doi.org/10.1182/blood.2020008824
Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. https://doi.org/10.1186/s13045-021-01177-0
Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309-1316. https://doi.org/10.1016/s1470-2045(20)30442-3
Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143-e161. https://doi.org/10.1016/s2352-3026(21)00283-0
Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033-3040. https://doi.org/10.1182/blood.2020008150
Martínez-López J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10(10):103. https://doi.org/10.1038/s41408-020-00372-5
Cook G, John Ashcroft A, Pratt G, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190(2):e83-e86. https://doi.org/10.1111/bjh.16874
Ho M, Zanwar S, Buadi FK, et al. Risk factors for severe infection and mortality in patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023;98(1):49-55. https://doi.org/10.1002/ajh.26762
Ludwig H, Sonneveld P, Facon T, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021;8(12):e934-e946. https://doi.org/10.1016/s2352-3026(21)00278-7
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11(8):138. https://doi.org/10.1038/s41408-021-00530-3
Ghandili S, Schonlein M, Wiessner C, et al. Lymphocytopenia and anti-CD38 directed treatment impact the serological SARS-CoV-2 response after prime boost vaccination in patients with multiple myeloma. J Clin Med. 2021;10(23):5499. https://doi.org/10.3390/jcm10235499
Henriquez S, Zerbit J, Bruel T, et al. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. Blood. 2022;139(6):942-946. https://doi.org/10.1182/blood.2021013714
Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39(8):1028-1030. https://doi.org/10.1016/j.ccell.2021.06.014
Nooka AK, Shanmugasundaram U, Cheedarla N, et al. Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma. J Clin Oncol. 2022;40(26):3057-3064. https://doi.org/10.1200/jco.21.02257
Faustini SE, Hall A, Brown S, et al. Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. Br J Haematol. 2023;201(5):845-850. https://doi.org/10.1111/bjh.18714
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood. 2022;139(9):1409-1412. https://doi.org/10.1182/blood.2021014989
Ntanasis-Stathopoulos I, Karalis V, Gavriatopoulou M, et al. Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, excluding those under anti-BCMA therapy. Hemasphere. 2022;6(8):e764. https://doi.org/10.1097/hs9.0000000000000764
Attolico I, Tarantini F, Carluccio P, et al. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. Br J Haematol. 2022;196(4):928-931. https://doi.org/10.1111/bjh.17873
Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e193. https://doi.org/10.1016/s2352-3026(20)30429-4
Dhakal B, Abedin S, Fenske T, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021;138(14):1278-1281. https://doi.org/10.1182/blood.2021012769
Salvini M, Maggi F, Damonte C, et al. Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation. Bone Marrow Transpl. 2022;57(1):137-139. https://doi.org/10.1038/s41409-021-01487-4
Busca A, Salmanton-García J, Marchesi F, et al. Outcome of COVID-19 in allogeneic stem cell transplant recipients: results from the EPICOVIDEHA registry. Front Immunol. 2023;14:1125030. PMID: 36911708. https://doi.org/10.3389/fimmu.2023.1125030
van Doesum JA, Salmanton-García J, Marchesi F, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T: an EPICOVIDEHA survey. Blood Adv. 2023;7(11):2645-2655. bloodadvances.2022009578 Online ahead of print. PMID: 37058479. https://doi.org/10.1182/bloodadvances.2022009578
Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773-2787. https://doi.org/10.1182/blood.2022017257
Wang L, Berger NA, Xu R. Risks of SARS-CoV-2 breakthrough infection and hospitalization in fully vaccinated patients with multiple myeloma. JAMA Netw Open. 2021;4(11):e2137575. https://doi.org/10.1001/jamanetworkopen.2021.37575
Sgherza N, Curci P, Rizzi R, et al. SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma. Blood Cancer J. 2021;11(12):201. https://doi.org/10.1038/s41408-021-00597-y
Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022;139(10):1588-1592. https://doi.org/10.1182/blood.2021014124
Ocon AJ, Ocon KE, Battaglia J, et al. Real-world effectiveness of tixagevimab and cilgavimab (evusheld) in patients with hematological malignancies. J Hematol. 2022;11(6):210-215. https://doi.org/10.14740/jh1062
Marchesi F, Salmanton-García J, Buquicchio C, et al. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. J Hematol Oncol. 2023;16(1):32. https://doi.org/10.1186/s13045-023-01423-7
Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(5):468-470. https://doi.org/10.1056/nejmc2207519
Spiliopoulou V, Ntanasis-Stathopoulos I, Malandrakis P, et al. Use of oral antivirals ritonavir-nirmatrelvir and molnupiravir in patients with multiple myeloma is associated with low rates of severe COVID-19: a single-center, prospective study. Viruses. 2023;15(3):704. https://doi.org/10.3390/v15030704
Salmanton-García J, Marchesi F, da Gomes Silva M, et al. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. EClinicalMedicine. 2023;58:101939. Epub 2023 Apr 6.PMID: 37041967. https://doi.org/10.1016/j.eclinm.2023.101939
Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34(8):2000-2011. https://doi.org/10.1038/s41375-020-0876-z
Salmanton-García J, Busca A, Cornely OA, et al. EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID-19. Hemasphere. 2021;5(7):e612. https://doi.org/10.1097/hs9.0000000000000612
Tivian XI GmbH. Experience-management Software. Accessed 28 December 2021. https://www.tivian.com/de/
COVID-19 clinical management. Living guidance World Health Organization. 2021. WHO/2019-nCoV/clinical/2021.1.
Mourad A, Thibault D, Holland TL, et al. Dexamethasone for inpatients with COVID-19 in a national cohort. JAMA Netw Open. 2023;6(4):e238516. https://doi.org/10.1001/jamanetworkopen.2023.8516
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. https://doi.org/10.1056/nejmoa2021436
Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2022;36(6):1467-1480. Epub 2022 Apr 29. PMID: 35488021; PMCID: PMC9053562.]. https://doi.org/10.1038/s41375-022-01578-1
Chuleerarux N, Manothummetha K, Moonla C, et al. Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2022;6(24):6198-6207. https://doi.org/10.1182/bloodadvances.2022008530
Schiller Salton N, Szwarcwort M, Tzoran I, et al. Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2021;96(12):E475-E478. https://doi.org/10.1002/ajh.26373
Goldwater MS, Stampfer SD, Sean Regidor B, et al. Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma. Clin Infect Pract. 2023;17:100214. https://doi.org/10.1016/j.clinpr.2022.100214
Aleman A, Van Oekelen O, Upadhyaya B, et al. Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell. 2022;40(5):441-443. https://doi.org/10.1016/j.ccell.2022.03.013
Enssle JC, Campe J, Büchel S, et al. Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma. Cancer Cell. 2022;40(6):587-589. https://doi.org/10.1016/j.ccell.2022.05.003
Salmanton-García J, Marchesi F, Glenthøj A, et al. Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine: an EPICOVIDEHA report. Hemasphere. 2022;6(11):e789. https://doi.org/10.1097/hs9.0000000000000789
Blennow O, Salmanton-García J, Nowak P, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report. Am J Hematol. 2022;97(8):E312-E317. https://doi.org/10.1002/ajh.26626
Terpos E, Rajkumar SV, Leung N. Neutralizing antibody testing in patients with multiple myeloma following COVID-19 vaccination. JAMA Oncol. 2022;8(2):201-202. https://doi.org/10.1001/jamaoncol.2021.5942
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. https://doi.org/10.1038/s41591-021-01377-8
Enßle JC, Campe J, Schwenger A, et al. Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. Blood. 2022;139(1):137-142. https://doi.org/10.1182/blood.2021013429
Gavriatopoulou M, Terpos E, Malandrakis P, et al. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. Br J Haematol. 2022;196(2):356-359. https://doi.org/10.1111/bjh.17841
Pratama NR, Wafa IA, Budi DS, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 omicron variant (B.1.1.529): a systematic review with meta-analysis and meta-regression. Vaccines (Basel). 2022;10(12):2180. https://doi.org/10.3390/vaccines10122180
Zou J, Kurhade C, Patel S, et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med. 2023;388(9):854-857. https://doi.org/10.1056/nejmc2214916
Wang L, Kaelber DC, Xu R, Berger NA. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: a clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022;54:100931. https://doi.org/10.1016/j.blre.2022.100931
Terpos E, Musto P, Engelhardt M, et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN) [published online ahead of print, 2023 May 4]. Leukemia. 2023:1-11.
